FEEDBACK
PLEASE WAIT ...
CLOSE
CLOSE

Country

USA USA

Industries

  • Medicine ‎1
    • Pharmaceuticals ‎1

Contact Info

Location

Novavax, Inc.

  • 1Product
  • 1Types
  • 1Industry

About Company

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis. Our product pipeline targets a variety of infectious diseases, with clinical vaccine candidates for respiratory syncytial virus (RSV), seasonal influenza and Ebola virus (EBOV) and a preclinical program for a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. Novavax is headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and is dedicated to developing novel vaccines to address infectious disease.

Products

NVX-CoV2373

MEDICINE - PHARMACEUTICALS   |  COVID-19 VACCINE

NVX-CoV2373

Properties :

Immune system enhancement,Immunogenicity,Enhancing antigens in local lymph nodes

Application :

Coronavirus,COVID-19

Analytical Reports